PAH is a rare condition in children, but is often fatal if left untreated, and protocols for pediatric patients have not been ...

In patients with familial PAH, SMAD5 appears to be a novel gene that warrants consideration for genetic testing, according to ...

Stanford University are preparing for a Phase II in Pulmonary Arterial Hypertension (PAH)Kiel, Germany, January 8, 2025 – ...

Steve Van Wormer has published nearly 500 podcasts about pulmonary hypertension (PH) — more than perhaps anyone working in rare diseases.

A Mendelian analysis supports the idea that hyperuricemia may be an important risk factor for pulmonary arterial hypertension ...

Pulmonary arterial hypertension (PAH) affected an estimated 192,000 individuals globally in 2021, disproportionately affecting women and older adults.

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...

Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...

Liquidia Corporation (NASDAQ: LQDA) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALG-801, Alivegen ’s experimental ...

AliveGen USA Inc. (AliveGen), a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALG-801 for the ...